HER2 positive advanced gastric cancer
Conditions
Interventions
TS-1 : 80mg/m2/day po on Days 1-14 Cisplatin : 60mg/m2 iv on Day 1 Trastuzumab : 8mg/kg iv on Day 1 (fist course), and 6mg/kg iv on Day 1 (from second course)
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed gastric cancer. 2. Patients who have HER2-positive cancer confirmed with IHC and/or FISH (IHC 3+ or IHC 2+ and FISH positive). 3. Age 20-80 4. Performance status (ECOG scale) 0 or 1. 5. No prior chemotherapy or radiotherapy for gastric cancer. Patients who received S-1+CDDP therapy until having diagnosed HER2-positive 6. Patients without brain metastasis. 7. Adequate baseline organ and marrow function as defined below; a. Leukocytes : 3,500-12,000/mm3 b. Absolute neutrophil count : >= 2,000/mm3 c. Platelets : >= 100,000/mm3 d. Hemoglobin : >= 9.0g/dL e. AST (SGOT)/ALT (SGPT) : < 100IU/L f. Total bilirubin : < 1.5mg/dL g. Serum creatinine : <= 1.2mg/dL h. Creatinine clearance : >= 60mL/min 8. Patients with left ventricular ejection fraction of at least 50% on MUGA (Multi Gated Acquisition Scan) or echocardiography done within 21 days before enrollment. 9. No abnormal findings requiring treatment in the electrocardiogram within 21 days before enrollment. 10. Patients able to take orally. 11. Patients should sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are contraindicated to S-1, CDDP, and Trastuzumab. 2. Women in pregnancy, at risk of pregnancy, hoping to become pregnant. Men who want their partners to become pregnant. 3. Patients with active infection. 4. Patients have Active hepatitis type B. 5.Serious illness or medical conditions as defined below; a. Patient with a previous history of congestive heart failure b. Hi-risk uncontrolled arrhythmias c. Unstable angina requiring medication d. Patient with a previous history of myocardial infarction e. Severe heart valve disease f. Patient with a previous history of transmural infarct g. Uncontrolled hypertension 6. Serious complication as followings ; a. Interstitial pneumonia b. Pulmonary fibrosis c. Heart failure d. Renal failure e. Hepatic failure f. Uncontrolled diabetes mellitus 7. Patients with fresh bleeding from gastric cancer and/or the digestive tract 8. Patients with diarrhea (4 or more times per day or watery diarrhea). 9.Second primary malignancy (except adequately treated basal cell carcinoma treated more than 5 years ago without recurrence) 10. Patients who are received systemic continuous administration of flucytosine, phenytoin, or warfarin. 11. Any patients judged by the investigator to be unfit to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety Overall survival (OS) Response rate (RR) | — |
Countries
Japan
Contacts
Public ContactAkihito Abe
Dokkyo Medical University Second Department of Surgery
Outcome results
None listed